3.74
price down icon1.19%   -0.045
after-market アフターアワーズ: 3.73 -0.01 -0.27%
loading
前日終値:
$3.785
開ける:
$3.8
24時間の取引高:
2.49M
Relative Volume:
1.45
時価総額:
$285.35M
収益:
$80.00M
当期純損益:
$-76.12M
株価収益率:
-3.2621
EPS:
-1.1465
ネットキャッシュフロー:
$-63.88M
1週間 パフォーマンス:
-0.53%
1か月 パフォーマンス:
-3.11%
6か月 パフォーマンス:
-46.42%
1年 パフォーマンス:
-56.00%
1日の値動き範囲:
Value
$3.71
$3.81
1週間の範囲:
Value
$3.71
$3.86
52週間の値動き範囲:
Value
$2.83
$15.74

Fulcrum Therapeutics Inc Stock (FULC) Company Profile

Name
名前
Fulcrum Therapeutics Inc
Name
セクター
Healthcare (1067)
Name
電話
617-651-8851
Name
住所
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Name
職員
55
Name
Twitter
@fulcrumtx
Name
次回の収益日
2026-11-04
Name
最新のSEC提出書
Name
FULC's Discussions on Twitter

Compare FULC vs VRTX, REGN, MRNA, ARGX, RVMD

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
FULC icon
FULC
Fulcrum Therapeutics Inc
3.74 285.35M 80.00M -76.12M -63.88M -1.1465
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
526.19 133.37B 12.34B 4.34B 3.71B 16.87
REGN icon
REGN
Regeneron Pharmaceuticals Inc
788.04 81.13B 14.92B 4.42B 3.79B 41.04
MRNA icon
MRNA
Moderna Inc
198.88 79.40B 2.23B -3.19B -1.60B -8.1462
ARGX icon
ARGX
Argen X Se Adr
959.49 60.03B 4.16B 1.29B 734.26M 19.58
RVMD icon
RVMD
Revolution Medicines Inc
204.97 43.93B 742.00K -1.37B -1.07B -7.0731

Fulcrum Therapeutics Inc Stock (FULC) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2026-01-12 開始されました JP Morgan Overweight
2025-11-24 開始されました Truist Buy
2025-07-29 アップグレード H.C. Wainwright Neutral → Buy
2025-05-23 アップグレード Leerink Partners Market Perform → Outperform
2025-05-15 アップグレード Cantor Fitzgerald Neutral → Overweight
2024-09-13 ダウングレード H.C. Wainwright Buy → Neutral
2024-09-12 ダウングレード BofA Securities Neutral → Underperform
2024-09-12 ダウングレード Cantor Fitzgerald Overweight → Neutral
2024-09-12 ダウングレード Leerink Partners Outperform → Market Perform
2024-09-12 ダウングレード RBC Capital Mkts Outperform → Sector Perform
2024-09-12 ダウングレード Stifel Buy → Hold
2024-09-09 アップグレード BofA Securities Underperform → Neutral
2024-05-20 開始されました Cantor Fitzgerald Overweight
2024-03-13 開始されました RBC Capital Mkts Outperform
2023-09-25 開始されました Goldman Neutral
2023-08-23 アップグレード H.C. Wainwright Neutral → Buy
2023-08-22 アップグレード Stifel Hold → Buy
2023-05-04 ダウングレード Goldman Buy → Neutral
2023-03-10 ダウングレード Credit Suisse Outperform → Neutral
2023-03-10 ダウングレード H.C. Wainwright Buy → Neutral
2023-03-09 ダウングレード Stifel Buy → Hold
2023-02-28 ダウングレード Morgan Stanley Overweight → Equal-Weight
2023-02-24 ダウングレード BofA Securities Neutral → Underperform
2022-11-15 開始されました Goldman Buy
2022-03-08 開始されました Oppenheimer Outperform
2022-03-03 アップグレード BofA Securities Underperform → Neutral
2021-08-11 アップグレード Morgan Stanley Equal-Weight → Overweight
2021-04-26 再開されました Credit Suisse Outperform
2021-03-22 開始されました Credit Suisse Outperform
2021-03-02 開始されました Stifel Buy
2020-10-16 開始されました Piper Sandler Overweight
2020-08-12 ダウングレード BofA Securities Neutral → Underperform
2020-08-12 繰り返されました H.C. Wainwright Buy
2020-08-12 ダウングレード Morgan Stanley Overweight → Equal-Weight
2020-06-19 ダウングレード BofA/Merrill Buy → Neutral
2020-06-17 開始されました BTIG Research Buy
2019-10-03 開始されました H.C. Wainwright Buy
2019-08-12 開始されました BofA/Merrill Buy
すべてを表示

Fulcrum Therapeutics Inc (FULC) 最新ニュース

pulisher
Sep 25, 2026

Kaplan Fox Announces an Investigation of Fulcrum Therapeutics, In - The National Law Review

Sep 25, 2026
pulisher
Sep 23, 2026

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Centerspace (NYSE – CSR), Fulcrum Therapeutics, Inc. (Nasdaq – FULC), Weave Communications, Inc. (NYSE – WEAV), Personalis, Inc. (Nasdaq – PSNL) - Supply Chain Digital Magazine

Sep 23, 2026
pulisher
Sep 23, 2026

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Centerspace (NYSE – CSR), Fulcrum Therapeutics, Inc. (Nasdaq – FULC), Weave Communications, Inc. (NYSE – WEAV), Personalis, Inc. (Nasdaq – PSNL) - GlobeNewswire Inc.

Sep 23, 2026
pulisher
Sep 23, 2026

Kaplan Fox Reminds Fulcrum Therapeutics, Inc. (NASDAQ: FULC) Investors of an Ongoing Securities Law Investigation - The National Law Review

Sep 23, 2026
pulisher
Sep 22, 2026

Fulcrum Therapeutics faces investigation after stock halves due to halted sickle cell drug program. - Pluang

Sep 22, 2026
pulisher
Sep 21, 2026

Fulcrum Therapeutics (FULC) Holds Steady at $3.77 as Traders Eye Range BoundariesBullish Pattern Stocks - siam.in

Sep 21, 2026
pulisher
Sep 21, 2026

Fulcrum Therapeutics (FULC) Edges Higher to $3.79 as Shares Test Upper RangeMomentum Trade - siam.in

Sep 21, 2026
pulisher
Sep 21, 2026

Kaplan Fox Urges Fulcrum Therapeutics, Inc. (NASDAQ: FULC) Invest - The National Law Review

Sep 21, 2026
pulisher
Sep 20, 2026

Fulcrum Therapeutics, Inc.(NasdaqGM:FULC) dropped from S&P Pharmaceuticals Select Industry Index - marketscreener.com

Sep 20, 2026
pulisher
Sep 12, 2026

Live Fulcrum Therapeutics, Inc. (FULC) Technical Analysis - Traders Union

Sep 12, 2026
pulisher
Sep 11, 2026

FULC Stock Slumps Nearly 50% After Hours As FDA Kills Only Clinical Program Over Cancer Risk - Stocktwits

Sep 11, 2026
pulisher
Sep 11, 2026

Kaplan Fox Notifies Fulcrum Therapeutics, Inc. (NASDAQ: FULC) Investors of an Investigation Into Possible Securities Law Violations - NewMediaWire

Sep 11, 2026
pulisher
Sep 11, 2026

Kaplan Fox Notifies Fulcrum Therapeutics, Inc. (NASDAQ: FULC) Inv - The National Law Review

Sep 11, 2026
pulisher
Sep 09, 2026

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: ... - pmg-ky3.com

Sep 09, 2026
pulisher
Sep 09, 2026

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire

Sep 09, 2026
pulisher
Sep 09, 2026

Kaplan Fox Alerts Fulcrum Therapeutics, Inc. (NASDAQ: FULC) Investors to an Ongoing Investigation Into Possible Securities Law Violations - NewMediaWire

Sep 09, 2026
pulisher
Sep 06, 2026

Kaplan Fox Alerts Fulcrum Therapeutics, Inc. (NASDAQ: FULC) Inves - The National Law Review

Sep 06, 2026
pulisher
Sep 05, 2026

FULC Stock Alert: Halper Sadeh LLC is Investigating Whether Fulcrum Therapeutics, Inc. is Obtaining a Fair Price for its Shareholders - The Daily Tribune News

Sep 05, 2026
pulisher
Sep 04, 2026

Kaplan Fox Investigates Fulcrum Therapeutics After Pociredir Discontinuation Triggers 51% Stock Collapse - kalkine.ca

Sep 04, 2026
pulisher
Sep 04, 2026

Kaplan Fox Launches Investigation Into Fulcrum Therapeutics Following 51% Stock Plunge After Pociredir Program Halt - Kalkine Media

Sep 04, 2026
pulisher
Sep 03, 2026

Kaplan Fox is Investigating Fulcrum Therapeutics, Inc. (NASDAQ: FULC) for Possible Securities Law Violations - The National Law Review

Sep 03, 2026
pulisher
Sep 02, 2026

Greg Tourangeau, Former Fulcrum Therapeutics Officer, to Sell 14,062 Shares Worth $54,420 - Kalkine Media

Sep 02, 2026
pulisher
Sep 02, 2026

Kaplan Fox Launches Securities Investigation Into Fulcrum Therapeutics After 51% Stock Collapse - kalkine.ca

Sep 02, 2026
pulisher
Sep 02, 2026

Former Fulcrum Therapeutics (FULC) officer moves to sell about $54K in stock - Stock Titan

Sep 02, 2026
pulisher
Sep 02, 2026

Fulcrum (NASDAQ: FULC) plans special cash dividend ahead of Slate Medicines merger - Stock Titan

Sep 02, 2026
pulisher
Aug 31, 2026

Fulcrum Therapeutics faces securities probe aft... - Pluang

Aug 31, 2026
pulisher
Aug 31, 2026

Fulcrum Therapeutics Inc. (FULC) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research

Aug 31, 2026
pulisher
Aug 27, 2026

Kaplan Fox is Investigating Possible Securities Law Violations Against Fulcrum Therapeutics, Inc. (NASDAQ: FULC) - The Globe and Mail

Aug 27, 2026
pulisher
Aug 26, 2026

Fulcrum Therapeutics Faces Securities Law Investigation After Pociredir Programme Discontinuation Triggers 51% Stock Drop - kalkine.ca

Aug 26, 2026
pulisher
Aug 25, 2026

Fulcrum (FULC) is Allocating 95% of the Combined Company to Slate and PIPE Investors. Is the $270M Dividend Enough? - Yahoo Finance

Aug 25, 2026
pulisher
Aug 24, 2026

Fulcrum (FULC) Close: Ends Up by 0.26% at $3.84; Chart View: the Price Remains Bounded by the Supplied Support and Resistance in the Latest SessionVolatility Smile - vinanet.vn

Aug 24, 2026
pulisher
Aug 24, 2026

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Fulcrum Therapeutics, Inc. (Nasdaq – FULC), Weave Communications, Inc. (NYSE – WEAV), Iridium Communications Inc. (Nasdaq – IRDM), Bio-Techne Corpo - mykxlg.com

Aug 24, 2026
pulisher
Aug 24, 2026

$HAREHOLDER ALERT: The M&A Class Action Firm Announce the Investigation of the MergerHOWL, HZO, TYFG and FULC - Sahm

Aug 24, 2026
pulisher
Aug 23, 2026

Fulcrum (FULC) Stock: Falls 0.52% to $3.83 at the Close; Chart View: Support at $3.64 and Resistance at $4.02 Frame the Range in the Latest SessionAnalyst Upgrade Stocks - vinanet.vn

Aug 23, 2026
pulisher
Aug 20, 2026

Fulcrum (FULC) Quarter in Focus: The Available Earnings Metric Delivers a Beat in the Current Update; Market Response: Shares Finish 1.03% Higher on the DayEnergy Earnings Report - dars.gov.et

Aug 20, 2026
pulisher
Aug 19, 2026

Fulcrum Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Fulcrum Therapeutics, Inc.FULC - Business Wire

Aug 19, 2026
pulisher
Aug 18, 2026

Fulcrum Therapeutics Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs

Aug 18, 2026
pulisher
Aug 18, 2026

Slate Medicines to Merge With Fulcrum Therapeutics - Cooley

Aug 18, 2026
pulisher
Aug 18, 2026

Kaplan Fox Encourages Investors of Fulcrum Therapeutics, Inc. (NA - The National Law Review

Aug 18, 2026
pulisher
Aug 18, 2026

Kaplan Fox Encourages Investors of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) to Contact the Firm Regarding an Investigation Into Possible Securities Law Violations - FinancialContent

Aug 18, 2026
pulisher
Aug 18, 2026

Truist Financial Maintains Fulcrum Therapeutics(FULC.US) With Hold Rating - Moomoo

Aug 18, 2026
pulisher
Aug 18, 2026

Fulcrum Therapeutics Strikes All-Stock Merger With Slate Medicines - Sahm

Aug 18, 2026
pulisher
Aug 18, 2026

Shareholder Alert: Ademi LLP investigates whether Fulcrum Therapeutics, Inc. is obtaining a Fair Price for Public Shareholders - Sahm

Aug 18, 2026
pulisher
Aug 18, 2026

Latham Advises Frazier Life Sciences on Private Placement Financing in Connection With Fulcrum Therapeutics and Slate Medicines Merger - Legal Desire

Aug 18, 2026
pulisher
Aug 17, 2026

Latham Advises Frazier Life Sciences on Private Placement Financing With Fulcrum Slate Merger - Latham & Watkins LLP

Aug 17, 2026
pulisher
Aug 17, 2026

Form 8K Fulcrum Therapeutics Inc For: 17 August By Investing.com - Investing.com South Africa

Aug 17, 2026
pulisher
Aug 17, 2026

Fulcrum Therapeutics and Slate Medicines Announce Merger Agreement with Key Financial Details - Kalkine Media

Aug 17, 2026
pulisher
Aug 17, 2026

Fulcrum Therapeutics (NASDAQ: FULC) backs $245M migraine venture with Slate - Stock Titan

Aug 17, 2026
pulisher
Aug 17, 2026

Fulcrum Therapeutics to Merge With Slate Medicines in $245 Million Backed Migraine Play - finance.biggo.com

Aug 17, 2026
pulisher
Aug 17, 2026

What's Going On With Fulcrum Therapeutics Stock Monday?Fulcrum Therapeutics (NASDAQ:FULC) - Benzinga

Aug 17, 2026
pulisher
Aug 17, 2026

Slate Medicines goes public via Fulcrum merger to challenge PACAP migraine field - AllSci

Aug 17, 2026

Fulcrum Therapeutics Inc (FULC) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$117.83
price down icon 3.06%
$35.80
price down icon 0.91%
$58.21
price down icon 0.14%
$255.96
price up icon 2.55%
ONC ONC
$360.85
price up icon 0.24%
$204.97
price up icon 2.56%
大文字化:     |  ボリューム (24 時間):